Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ascendis Pharma A (ASND) EBT (2016 - 2025)

Historic EBT for Ascendis Pharma A (ASND) over the last 12 years, with Q4 2025 value amounting to -$31.1 million.

  • Ascendis Pharma A's EBT rose 2217.8% to -$31.1 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$236.2 million, marking a year-over-year increase of 4166.89%. This contributed to the annual value of -$240.3 million for FY2025, which is 3974.65% up from last year.
  • Latest data reveals that Ascendis Pharma A reported EBT of -$31.1 million as of Q4 2025, which was up 2217.8% from -$67.1 million recorded in Q3 2025.
  • In the past 5 years, Ascendis Pharma A's EBT ranged from a high of -$31.1 million in Q4 2025 and a low of -$206.2 million during Q4 2022
  • In the last 5 years, Ascendis Pharma A's EBT had a median value of -$112.7 million in 2024 and averaged -$110.6 million.
  • In the last 5 years, Ascendis Pharma A's EBT crashed by 8504.18% in 2022 and then surged by 6628.78% in 2025.
  • Ascendis Pharma A's EBT (Quarter) stood at -$121.5 million in 2021, then crashed by 69.73% to -$206.2 million in 2022, then surged by 57.68% to -$87.2 million in 2023, then surged by 54.21% to -$39.9 million in 2024, then increased by 22.18% to -$31.1 million in 2025.
  • Its EBT stands at -$31.1 million for Q4 2025, versus -$67.1 million for Q3 2025 and -$39.6 million for Q2 2025.